MolecularPathology.ca

 
Faculty Kingston

David P. LeBrun, MD

Associate Professor of Department of Pathology and Molecular Medicine (Site Leader of the Training Program)

Dr. LeBrun obtained his M.D. from Queen’s University, residency training in Anatomical Pathology at the University of Toronto, and training in molecular oncology as an MRC Research Fellow at Stanford University. He has held a faculty appointment in the Department of Pathology at Queen’s University since 1994, where is he currently an Associate Professor and consultant in lymph node pathology for Southeastern Ontario. Dr. LeBrun's experimental research program is focused on the mechanistic role of oncogenic transcription factors, particularly E2A-PBX1, in acute leukemia. He has also initiated correlative studies relating to malignant lymphoma. He research has been supported by multiple external agencies, including the Canadian Institutes for Health Research (CIHR), the National Cancer Institute of Canada (NCIC), the Ontario Institute for Cancer Research (OICR) and the Cancer Research Society (CRS).

The link to our lab website is:http://www.lebrunlabs.ca/index.php/publisher/articleview/frmArticleID/2/

Jeremy Squire, PhD

 

Professor of the Department of Molecular Medicine

Dr. Squire is Professor and Research Chair in the Department of Pathology and Molecular Medicine at Queen's University and Kingston General Hospital; and, Director of Translational Laboratory Research, NCIC - Clinical Trials Group.  Dr. Squire's program is strongly oriented towards translational research using molecular, genomic and cytogenetic methods to provide new information and hypotheses concerning the onset, cause and progression of cancer.  Dr. Squire has been a champion of molecular cytogentic cancer research and was among the first in the world to develop and apply spectral karyotyping (SKY), microarray comparative genomic hybridization, and molecular analysis of epigenomic changes in tumours.  His research group has been among the most productive in this field, with over 250 original peer-reviewed papers, chapters and reviews in the area of the molecular cytogentics and the genomics of solid tumours and leukemias. 

With a strong reputation in the use of novel sophisticated technologies for the detection of cancer, he has elucidated processes that are operative during early steps of tumour initiation, particularly on multiple changes during this process that affect genes, chromosomes and proteins. 

Dr. Squire retired in 2013.

Victor Tron, MD

Professor of Department of Pathology and Molecular Medicine

As a senior clinician scientist, Dr. Tron has maintained an active research program that continues to be supported by the Canadian Institutes of Health Research. His research interests revolve around mechanism of melanoma pathogenesis. The current focus is on the role of microRNAs in malignant melanoma and the use of siRNA for therapeutic purposes. Dr. Tron collaborates with scientists at Queen's University, the University of Alberta and Rockefeller University in New York.

Dr. Tron moved to St. Michael’s Hospital in Toronto in 2014 and is no longer involved in this program.

Victor Tron's Publications: http://www.ncbi.nlm.nih.gov/sites/entrez

 

Michael Rauh, MD, PhD

Assistant Professor and Attending Hematopathologist, Department of Pathology and Molecular Medicine, Queen’s University

Dr. Rauh obtained his MD/PhD training at the University of British Columbia and Terry Fox Laboratory of the BC Cancer Agency. Residency training in Hematological Pathology was conducted at the University of Toronto. Dr. Rauh is an alumnus of the joint American Society of Hematology/European Hematology Agency Translational Research Training in Program Hematology (TRTH). He has held a faculty appointment in the Department of Pathology at Queen’s University since 2011, where is he currently an Assistant Professor and consultant in Hematopathology. In 2014, he was appointed as a Transformative Pathology Fellow of the Ontario Institute for Cancer Research. Dr. Rauh's experimental research program is focused on the development of novel somatic mutation and digital gene expression assays to improve myeloid cancer diagnosis, risk and treatment stratification. Moreover, Dr. Rauh aims to elucidate clone-immune environment interactions to inform novel therapeutic directions in bone marrow failure. His research has been supported by the Canada Foundation for Innovation (CFI), Southeastern Ontario Academic Medical Organization (SEAMO), University Hospitals Kingston Foundation (UHKF), Clinical Teachers’ Association of Queen’s (CTAQ), the Canadian Hematology Society (CHS), Canadian Cancer Society Research Institute (CCSRI), and the Ontario Institute for Cancer Research (OICR).

Link to website: http://www.queensu.ca/rauhlab/research

Harriet Feilotter, PhD, FCCMG

Associate Professor, Dept. of Pathology and Molecular Medicine, Queen's University Service Chief, Laboratory Genetics, Kingston General Hospital

Dr. Feilotter is an Associate Professor in the Department of Pathology and Molecular Medicine at Queen’s University, where she maintains an active research program dedicated to biomarker discovery and validation in a variety of human diseases. She also oversees the genomic and proteomic laboratory operations of Indoc Research, a not for profit service provider of laboratory and informatics services with a special interest in the integration of platforms designed to support large-scale studies of human DNA, RNA and proteins. In her role as Service Chief of Kingston General Hospital Laboratory Genetics, she also oversees the clinical genetics program. This combination of job responsibilities allows her to focus on methods to bridge the gap between research and clinical application of biomarker findings.

Last Updated ( June 4, 2015)